

You are invited!

Guiding Multiple Myeloma Patients on their Treatment Journey

Presented by
Rhonda L. Hewitt, MSN, RN, ANP, AOCNP
Nurse Practitioner
Stanford Health Care

Wednesday, June 13, 2018

6:30 PM

Fogo de Chao
377 Santana Row, Suite 1090, San Jose, CA 95128
(408) 244-7001

Hosted by
Hank Schwarz
Senior Oncology Specialist
Takeda

**RSVP via e-mail to takedarsvp@theselvagroup.com or fax to (800) 660-8857
before 06/11/2018.**

NINLARO® (ixazomib) is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Full Name	Credentials	Title		
Institution		City	State	ZIP Code
Email Address		Phone		
		E17067		
License Number (only if licensed in MA or MN)		Meeting Code		

Sponsored by Takeda. Please note that this is not a continuing medical education (CME) program.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

- **Thrombocytopenia** has been reported with NINLARO. During treatment, monitor platelet counts at least monthly, and consider more frequent monitoring during the first three cycles. Manage thrombocytopenia with dose modifications and platelet transfusions as per standard medical guidelines. Adjust dosing as needed. Platelet nadirs occurred between Days 14-21 of each 28-day cycle and typically recovered to baseline by the start of the next cycle.

**Please see additional Important Safety Information continued on page 2
and accompanying NINLARO (ixazomib) full Prescribing Information.**

 **NINLARO®**
(ixazomib) capsules
4mg | 3mg | 2.3mg